A*STAR Experimental Drug Development Centre (A*STAR EDDC)

A*STAR’s steady investments in R&D and talent create the ideal conditions for impactful science, says its Chief Executive Officer Frederick Chew.

Contrary to popular belief, a new A*STAR study shows that HIV mutations are far from random, emerging at specific locations at specific rates.

The discovery of a new, highly conserved druggable site on the HIV reverse transcriptase could turn the tide in the wake of growing drug resistance.

A*STAR scientists aim to design better immunotherapies by simulating the binding of antibodies to their targets.